Last reviewed · How we verify
Ioflupane I 123 (IOFLUPANE)
Ioflupane I-123 binds to the dopamine transporter (DaT) in the striatum, allowing visualization of brain striata through SPECT imaging.
Ioflupane I 123 (ioflupane) is a radioactive diagnostic agent used to visualize the brain's dopamine system. It is a small molecule that targets serotonin reuptake, but its primary use is in diagnosing suspected Parkinsonian syndromes and suspected dementia with Lewy bodies. Ioflupane I 123 is owned by Ge Healthcare Inc and was approved by the FDA in 2023. It is available as a generic medication and is off-patent, with one generic manufacturer listed. Key safety considerations include the radioactive nature of the agent, which requires proper handling and disposal.
At a glance
| Generic name | IOFLUPANE |
|---|---|
| Sponsor | Ge Hlthcare Inc |
| Drug class | Radioactive Diagnostic Agent [EPC] |
| Target | Dopamine transporter (DaT) |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 2023 |
Mechanism of action
Ioflupane I-123 is a radiotracer that binds specifically to the dopamine transporter (DaT) in the brain's striatum. When administered, it emits gamma radiation detectable by SPECT imaging, enabling visualization of the striatal regions involved in dopamine transport.
Approved indications
- suspected Parkinsonian syndromes
- suspected dementia with Lewy bodies
Common side effects
- Hypersensitivity
- Injection site pain
- Dyspnea
- Edema
- Rash
- Erythema
- Pruritus
- Headache
- Nausea
- Vertigo
- Dry mouth
- Dizziness
Drug interactions
- amoxapine
- amphetamine
- armodafinil
- benztropine
- bupropion
- buspirone
- cocaine
- mazindol
- methamphetamine
- methylphenidate
- modafinil
- norephedrine
Key clinical trials
- DaTSCAN Imaging in Aging and Neurodegenerative Disease (PHASE4)
- Terazosin and Parkinson's Disease Extension Study (PHASE2)
- Cardiac Changes in Early Parkinson's Disease: A Follow up Study (PHASE2)
- Terazosin Effect on Cardiac Changes in Early Parkinson's Disease (PHASE2)
- Markers of Disease Progression and Gait Within the Parkinsonian Population (NA)
- [18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor (PHASE3)
- Molecular and Functional Imaging in Monogenic PD.
- Video-oculography and Parkinson's Disease (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ioflupane I 123 CI brief — competitive landscape report
- Ioflupane I 123 updates RSS · CI watch RSS
- Ge Hlthcare Inc portfolio CI